Decoy Therapeutics Inc. Common Stock Small cap showcase Conference

At the uplifting or potential acquisition, and obviously a team extremely experienced in being able to do this and bring this to the next level. So I think, really, when you look at all that and you look at what we've been able to do and how our finances are, we're good to go financially, till past 27, and to hit all the milestones that we're saying along the way. Potentially, in the near future, we'll be considering raising money again, potentially, but maybe not. Well, we'll see how that goes. And then I think you could see here how even the structure of the company we believe so much in this, that as founders we put our own money in this as well. So what they say, "Put your money where your mouth is, and if you believe it, you do it." And that's what we've been doing. Well, thank you very much. Any questions? Let's open it up to some questions if that's okay with you, sir.

And for our webcast, please speak your question in the microphone.

Yes. Is the phase one trial an open label trial? And the other question that I have is, I forgot.

Yeah. Yeah, absolutely. So the phase one dose escalation has to be open label because we need to know what we're giving to the patient. And it's the only way for us to get to the dose. So absolutely, it's open label. And as for your second question, I don't know.

We have a question over here. Excuse me, sir. So any licensing agreements with any of the pharma companies?

So yeah, that's the goal. As I said before, we've started discussions with many companies. Right now, we have five NDAs out of the seven that we started. So there's we've already been told what they're expecting. For an agreement to occur. And that's what we're working on. So we've taken those marching orders and are moving with them. Yep. Take it remembered. Is there an answer to that question?

How many patients are enrolled in the phase one trial, and when will it get underway?

So phase one trial has already started. We've put in about more than 54 patients. As we climb up the doses to be able to get to the dose that would be appropriate, there is a caveat. The FDA requires that as we move past dose escalation, that we identify two doses. It is something called Project Optimus, where it makes us look at two potential doses going in for the next level. And that's really to make sure that any safety data would be captured. And then from there, they weigh the effect versus safety, and we decide from there which one we move forward.

Thank you. For your presentation.

I have a question about whatever data you might be reporting in your second half, and what investors should we be paying attention to in that data?

Yeah. So we would be looking at getting the initial safety data from our phase one dose escalation. Secondary endpoints to the study shows we would be capturing efficacy data as well. So some of that would be reported. And really, at that point, investors that we've been really talking to, and the ones that are really I would say more effective in this, are ones that are industry related, and they understand. So institutional investors that have been in the space really kind of pay attention at that point. So you'll see who they are. I mean, there are multiple out there, and there's a few names that pop out, and everyone knows about. But really, around that data set time is really when you'll see a lot of these investors come through.

Just talk a little bit about the 80% clinical benefit rate for fish line patients.

Sure. Yeah. So really, for us, it's important that when you look at a patient that's received so many lines of therapy, the worry is that at that point, they're so far gone, it's very, very difficult to see any sort of effect. The fact that we got to see for the patients having absolute stasis of the tumor, where it's just it stopped growing, which is great, or it didn't grow at a rate that we thought it would grow, but then the one patient received almost what was considered a full PR, so partial response, so the cutoff is like 30, 132, and we were like at 29, 30. So we're right there. And this is really at a non-optimum dose yet. So when you look at that, saying 80% CBR, and we're not even at the dose there yet, and we haven't even gotten the formulation that is absorbed properly well yet, shows a lot. So we're believing that now with this new formulation, we really should be getting data that is more indicative of if the absorption is right, the exposure levels are correct, this is what we should be seeing.

Thank you, sir. Could you define your IP and what it covers?